<
https://www.cidrap.umn.edu/covid-19/antihistamine-nasal-spray-prevents-covid-19-study-finds>
'Results from a single-center randomized controlled trial published yesterday
in
JAMA Internal Medicine show that azelastine, an antihistamine nasal spray
used as a preventive measure, was associated with a 69% reduction of COVID-19
infection.
Azelastine is a widely available over-the-counter treatment for seasonal
allergies (hay fever).
"This clinical trial is the first to demonstrate a protective effect in a
real-world setting," said Robert Bals, MD, PhD, a professor at Saarland
University in Germany and senior author of the study, in a university press
release.
The trial involved 450 participants who were divided into two groups: The
treatment group (227) used an azelastine nasal spray three times a day over a
56-day period, while 223 participants in the control group used a placebo spray
three times a day. The average age of participants was 33, and 66% were women.
At the start of the trial, all participants, healthy adults from 18 to 65,
showed no signs of an acute infection, and had negative SARS-CoV-2 rapid
antigen test results.'
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
